v3.25.4
Acquisitions, Divestitures, Equity-Method Investments, Collaborative Arrangements, Research and Development Arrangements and In-Licensing Arrangements - Research and Development Arrangement (Details) - USD ($)
$ in Millions
 1 Months Ended 12 Months Ended
Sep. 28, 2025
Mar. 30, 2025
Apr. 30, 2023
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Abingworth [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development arrangement, maximum funding amount $ 200          
Research and development arrangement, funding to offset costs incurred       $ 54    
Abingworth [Member] | Clinical Trial Agreement Terms [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Maximum potential consideration $ 120          
Abingworth [Member] | Approval Based Payment Period [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payment period (in years) 18 months          
Abingworth [Member] | Net Sales and Royalty Agreement Terms [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Maximum potential consideration $ 280          
Payment period (in years) 1 year          
Blackstone [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development arrangement, maximum funding amount   $ 326        
Blackstone [Member] | Clinical Trial Agreement Terms [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Maximum potential consideration   277        
Blackstone [Member] | Net Sales and Royalty Agreement Terms [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Maximum potential consideration   $ 897        
Blackstone - March 2025 Arrangement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development arrangement, funding to offset costs incurred       102    
Blackstone - March 2025 Arrangement [Member] | Approval Based Payment Period [Member] | Minimum [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payment period (in years)   1 year        
Blackstone - March 2025 Arrangement [Member] | Approval Based Payment Period [Member] | Maximum [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payment period (in years)   3 years        
Blackstone - March 2025 Arrangement [Member] | Net Sales and Royalty Agreement Terms [Member] | Minimum [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payment period (in years)   5 years        
Blackstone - March 2025 Arrangement [Member] | Net Sales and Royalty Agreement Terms [Member] | Maximum [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payment period (in years)   7 years        
Blackstone - April 2023 Arrangement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development arrangement, maximum funding amount     $ 550      
Research and development arrangement, funding to offset costs incurred       $ 57 $ 135 $ 175
Blackstone - April 2023 Arrangement [Member] | Clinical Trial Agreement Terms [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Maximum potential consideration     468      
Blackstone - April 2023 Arrangement [Member] | Net Sales and Royalty Agreement Terms [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Maximum potential consideration     $ 550